Who are QLG1080's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Liraglutide Pen Injector [Saxenda], Liraglutide injection, Dulaglutide Pen, Liraglutide Pen Injector [Victoza], Benaglutide Injection, Lixisenatide (AVE0010).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/qlg1080.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

QLG1080 — Competitive Intelligence Brief

QLG1080 (QLG1080) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist. Area: Diabetes.

phase 3 GLP-1 receptor agonist GLP-1R Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

QLG1080 (QLG1080) — Qilu Pharmaceutical Co., Ltd.. QLG1080 is a GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
QLG1080 TARGET	QLG1080	Qilu Pharmaceutical Co., Ltd.	phase 3	GLP-1 receptor agonist	GLP-1R
Liraglutide Pen Injector [Saxenda]	Liraglutide Pen Injector [Saxenda]	University College, London	marketed	GLP-1 receptor agonist	GLP-1R (GLP-1 receptor)
Liraglutide injection	Liraglutide injection	Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca	marketed	GLP-1 receptor agonist	GLP-1R
Dulaglutide Pen	Dulaglutide Pen	Eli Lilly and Company	marketed	GLP-1 receptor agonist	GLP-1R
Liraglutide Pen Injector [Victoza]	Liraglutide Pen Injector [Victoza]	Imperial College London	marketed	GLP-1 receptor agonist	GLP-1R
Benaglutide Injection	Benaglutide Injection	The Affiliated Hospital of Qingdao University	marketed	GLP-1 receptor agonist	GLP-1R
Lixisenatide (AVE0010)	Lixisenatide (AVE0010)	Sanofi	marketed	GLP-1 receptor agonist	GLP-1R

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1 receptor agonist class)

Hanmi Pharmaceutical Company Limited · 30 drugs in this class
Eli Lilly and Company · 8 drugs in this class
Novo Nordisk A/S · 6 drugs in this class
GlaxoSmithKline · 6 drugs in this class
Sanofi · 4 drugs in this class
AstraZeneca · 4 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
Hangzhou Sciwind Biosciences Co., Ltd. · 3 drugs in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 2 drugs in this class
Huons Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). QLG1080 — Competitive Intelligence Brief. https://druglandscape.com/ci/qlg1080. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab